Vascular endothelial growth factor in inflammatory bowel disease: A systematic review and meta-analysis.

IF 4.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

European Journal of Clinical Investigation Pub Date : 2024-11-15 DOI:10.1111/eci.14361

Stefano Zoroddu, Biagio Di Lorenzo, Panagiotis Paliogiannis, Arduino A Mangoni, Ciriaco Carru, Angelo Zinellu

{"title":"Vascular endothelial growth factor in inflammatory bowel disease: A systematic review and meta-analysis.","authors":"Stefano Zoroddu, Biagio Di Lorenzo, Panagiotis Paliogiannis, Arduino A Mangoni, Ciriaco Carru, Angelo Zinellu","doi":"10.1111/eci.14361","DOIUrl":null,"url":null,"abstract":"Aim: Vascular endothelial growth factor (VEGF) is linked to inflammation and angiogenesis, indicating a possible role in inflammatory bowel disease (IBD) and its main clinical manifestations, Crohn's disease (CD) and ulcerative colitis (UC). This systematic review and meta-analysis investigated studies assessing circulating VEGF concentrations in IBD patients and healthy controls, considering the effect of IBD type, sample type and geographical location.Methods: A systematic search identified 18 studies (28 group comparators) investigating 1741 IBD patients and 1291 controls. Data were extracted and analysed using standardized mean differences (SMD) with 95% confidence intervals (CI).Results: VEGF concentrations were significantly higher in IBD patients (SMD = .71, 95% CI .38 to 1.04; p < .001). UC patients showed higher VEGF concentrations than CD patients. Serum samples indicated significant VEGF elevations, unlike plasma samples. Significant VEGF increases were observed in studies conducted in Western Europe and Asia, but not in Eastern Europe. No significant differences were found between active and inactive disease.Conclusions: VEGF concentrations are elevated in IBD patients, with variations by disease type, sample type and geography. However, VEGF is not a reliable marker of disease activity. Future research should standardize methods and explore regional influences to enhance VEGF's clinical utility as a biomarker of IBD.","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e14361"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.14361","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Vascular endothelial growth factor (VEGF) is linked to inflammation and angiogenesis, indicating a possible role in inflammatory bowel disease (IBD) and its main clinical manifestations, Crohn's disease (CD) and ulcerative colitis (UC). This systematic review and meta-analysis investigated studies assessing circulating VEGF concentrations in IBD patients and healthy controls, considering the effect of IBD type, sample type and geographical location.

Methods: A systematic search identified 18 studies (28 group comparators) investigating 1741 IBD patients and 1291 controls. Data were extracted and analysed using standardized mean differences (SMD) with 95% confidence intervals (CI).

Results: VEGF concentrations were significantly higher in IBD patients (SMD = .71, 95% CI .38 to 1.04; p < .001). UC patients showed higher VEGF concentrations than CD patients. Serum samples indicated significant VEGF elevations, unlike plasma samples. Significant VEGF increases were observed in studies conducted in Western Europe and Asia, but not in Eastern Europe. No significant differences were found between active and inactive disease.

Conclusions: VEGF concentrations are elevated in IBD patients, with variations by disease type, sample type and geography. However, VEGF is not a reliable marker of disease activity. Future research should standardize methods and explore regional influences to enhance VEGF's clinical utility as a biomarker of IBD.

查看原文本刊更多论文

炎症性肠病中的血管内皮生长因子：系统回顾与荟萃分析。

目的：血管内皮生长因子（VEGF）与炎症和血管生成有关，表明它可能在炎症性肠病（IBD）及其主要临床表现--克罗恩病（CD）和溃疡性结肠炎（UC）中发挥作用。本系统综述和荟萃分析调查了评估 IBD 患者和健康对照组循环血管内皮生长因子浓度的研究，并考虑了 IBD 类型、样本类型和地理位置的影响：系统性搜索确定了 18 项研究（28 组比较者），调查了 1741 名 IBD 患者和 1291 名对照者。采用标准化均值差异（SMD）和 95% 置信区间（CI）对数据进行提取和分析：结果：IBD 患者的血管内皮生长因子浓度明显较高（SMD = .71，95% CI .38 至 1.04；P 结论：IBD 患者的血管内皮生长因子浓度较高：IBD 患者体内的血管内皮生长因子浓度升高，不同疾病类型、样本类型和地域的患者体内的血管内皮生长因子浓度存在差异。然而，血管内皮生长因子并不是疾病活动的可靠标志物。未来的研究应规范方法并探索地区影响因素，以提高血管内皮生长因子作为 IBD 生物标记物的临床实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Investigation 医学-医学：内科

CiteScore

9.50

自引率

3.60%

发文量

192

审稿时长

1 months

期刊介绍： EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.